EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

Adjuvant Therapy After Pathologic Complete Response to Neoadjuvant Immunochemotherapy in Non–Small Cell Lung Cancer: A Multicenter Retrospective Real-World Study

Haoran Liu, Zhitao Gu, Keke Yu, Ze-Rui Zhao, Wanpu Yan, Yifan Fang, Xiangyang Yu, Long Jiang, Yiyang Wang

Clinical Lung Cancer · 2026-05 · 27 (4) · 160-169.e5

DOI: 10.1016/j.cllc.2026.03.015 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Lung Cancer, 2026-05. Verfasst von Haoran Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Shanghai Key Laboratory o…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Immunotherapy, Lung Neoplasms, Neoadjuvant Therapy. Die Arbeit nennt 29 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shanghai Science and Technology Development Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Whether resectable stage II to IIIB non-small cell lung cancer (NSCLC) patients could benefit from adjuvant therapy when pathologic complete response (pCR) is achieved after neoadjuvant immunochemotherapy remains unclear. METHODS We conducted a multicenter retrospective real-world study including patients with resectable stage II to IIIB NSCLC who achieved pCR after neoadjuvant immunochemotherapy and curative-intent resection between January 2020 and December 2023. Patients were categorized according to receipt of adjuvant systemic therapy or surveillance alone. Disease-free survival (DFS) was the primary outcome. Overall survival (OS), cancer-specific survival, recurrence patterns, and treatment-related adverse events (TRAE) were secondary outcomes. Propensity score matching and multivariable Cox regression were used for survival analyses. RESULTS Among 214 eligible patients, 133 received adjuvant therapy and 81 underwent surveillance. During a median follow-up of 29.5 months, 25 patients experienced recurrence and 11 died. After propensity score matching, 148 patients (74 per group) were included. In the matched cohort, adjuvant therapy was not associated with improved DFS (pair-stratified hazard ratio [HR] 1.22, 95% confidence interval [CI] 0.51-2.95) or OS (pair-stratified HR 1.00, 95% CI 0.20-4.96) compared with surveillance alone. Recurrence after pCR was predominantly distant. Grade 3 or higher TRAEs were observed in 18% of patients who received adjuvant therapy. CONCLUSIONS In patients achieving pCR after neoadjuvant immunochemotherapy, adjuvant systemic therapy was not associated with improved survival outcomes compared with surveillance alone and was accompanied by treatment-related toxicity. These findings suggest postoperative surveillance may be an appropriate consideration in discussions of postoperative management after confirmed pCR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungImmunotherapyLung NeoplasmsNeoadjuvant TherapyAgedFemaleHumansMaleMiddle AgedChemotherapy, AdjuvantPathologic Complete ResponseRetrospective Studies

Stichwörter der Autor:innen

Immune-Related ToxicitiesPostoperative ManagementReal-World EvidenceRecurrence PatternsSurvival Analysis

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Shanghai Key Laboratory of Thoracic Tumor Biotherapy, Shanghai Chest Hospital, Shanghai Jiao To…
  • Shanghai Key Laboratory of Thoracic Tumor Biotherapy, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Department of Pathology, Shanghai Chest Hospital, Shanghai Jiao Tong Univ…
  • Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), First Department of Thoracic Surgery, Peking University Cancer Hospital & Institute, Beijing, China.
  • Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, Ch…
  • Shanghai Key Laboratory of Thoracic Tumor Biotherapy, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Department of Oncological Surgery, Shanghai Chest Hospital, Shanghai Jiao…

Förderung

  • National Natural Science Foundation of China
  • Shanghai Science and Technology Development Foundation

Zitieren

APA

Liu, H., Gu, Z., Yu, K., Zhao, Z. R., Yan, W., Fang, Y., Yu, X., Jiang, L., & Wang, Y. (2026). Adjuvant Therapy After Pathologic Complete Response to Neoadjuvant Immunochemotherapy in Non–Small Cell Lung Cancer: A Multicenter Retrospective Real-World Study. Clinical Lung Cancer, 27(4), 160-169.e5. https://doi.org/10.1016/j.cllc.2026.03.015

Vancouver

Liu H, Gu Z, Yu K, Zhao ZR, Yan W, Fang Y, et al. Adjuvant Therapy After Pathologic Complete Response to Neoadjuvant Immunochemotherapy in Non–Small Cell Lung Cancer: A Multicenter Retrospective Real-World Study. Clinical Lung Cancer. 2026;27(4):160-169.e5. doi:10.1016/j.cllc.2026.03.015

BibTeX
@article{Liu2026,
  author = {Liu, Haoran and Gu, Zhitao and Yu, Keke and Zhao, Ze-Rui and Yan, Wanpu and Fang, Yifan and Yu, Xiangyang and Jiang, Long and Wang, Yiyang},
  title = {Adjuvant Therapy After Pathologic Complete Response to Neoadjuvant Immunochemotherapy in Non–Small Cell Lung Cancer: A Multicenter Retrospective Real-World Study},
  journal = {Clinical Lung Cancer},
  year = {2026},
  volume = {27},
  number = {4},
  pages = {160--169.e5},
  doi = {10.1016/j.cllc.2026.03.015}
}
Kostenlos starten →